RxDoctor Payments Data

Foma Munoh Kenne, MD

Internal Medicine · Staten Island, NYNPI 1972039378

Payments from drug & device makers

$24,267in general payments, 2019–2025

Across 214 payments — averaging $113.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$18K
  • E.r. Squibb & Sons, L.L.C.$918
  • GSK$502
  • Merck$493
  • Johnson & Johnson$432
  • Novartis$350
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$6,98397%
  • Education$1843%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,267 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$97,147
Medicare patients
247
Services billed
830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide33$469,183
VerzenioAbemaciclib18$279,182
Lenalidomide21$265,667
LorbrenaLorlatinib11$226,966
SprycelDasatinib11$132,339
XareltoRivaroxaban39$41,913
EliquisApixaban53$37,515
Imatinib Mesylate11$17,986
Anastrozole189$3,810
Hydroxyurea77$1,744
Dexamethasone72$1,430
Prochlorperazine Maleate73$1,136
Tamoxifen Citrate48$1,032
Exemestane13$950
Lidocaine-PrilocaineLidocaine/Prilocaine47$882

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$77$469,18333 claims
Lilly USA, LLCVerzenio, Olanzapine$39$279,89142 claims
PfizerLorbrena, Eliquis$109$264,48064 claims
E.r. Squibb & Sons, L.L.C.Sprycel$918$132,33911 claims
Johnson & JohnsonXarelto$432$41,91339 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →